BioSpace News Archive

AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease.

Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets.

Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces a contractual partnership with Rigel Pharmaceuticals, Inc., effective July 1, 2024, bringing its comprehensive suite of services to support patients using GAVRETO® (pralsetinib).

LSL PHARMA GROUP INC. announced that it has met the closing conditions of a non-brokered private placement for $1,5 million representing the first closing of the private placement financing announced on June 5, 2024.

Anumana, a leading AI-driven health technology company and portfolio company of nference, announced a new study that revealed promising results in support of further development of its investigational pulmonary hypertension (PH) algorithm.

The Association for Diagnostics & Laboratory Medicine is pleased to announce that Representatives John Joyce, MD, and Cathy McMorris Rodgers are the recipients of ADLM’s Outstanding Legislator Awards for the 118th Congress.

The Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees who are poised to redefine what is possible in cancer research.

Medical robotics innovatorNoah Medical today announced the final results from its FRONTIER Study, the platform’s first-in-human clinical trial testing the “Tool-in-Lesion” accuracy of its Galaxy System™, are now available for review in the Official Journal of the Asian Pacific Society of Respirology.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the “Meeting”) held virtually via live audio webcast, on June 26, 2024.